EGFR‐TKIs has become an vital systemic treatment in patients with MPE‐NSCLC on account of adenocarcinoma as the predominant pathological type,28 which has a high rate of EGFR‐M, especially in the Asian population.40 This evidence concerns the gene EGFR and non-small cell lung carcinoma.